Rosemary Lord

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Andrew R. Clamp, Elizabeth C James, Iain A. McNeish et al. · The Lancet · 2019 · 213 citations · Full text

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

R.P. Symonds, Charlie Gourley, S.E. Davidson et al. · The Lancet Oncology · 2015 · 112 citations · Full text

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

Martin Gore, Allan Hackshaw, William E. Brady et al. · Gynecologic Oncology · 2019 · 98 citations · Full text

Meoc/gog 0241, Gynecological Surgery, Medicine +9

Adenovirus Type 9 Fiber Knob Binds to the Coxsackie B Virus-Adenovirus Receptor (CAR) with Lower Affinity than Fiber Knobs of Other CAR-Binding Adenovirus Serotypes

Ian Kirby, Rosemary Lord, Elizabeth Davison et al. · Journal of Virology · 2001 · 57 citations · Full text

Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Robert D. Morgan, Iain A. McNeish, Adrian Cook et al. · The Lancet Oncology · 2020 · 56 citations · Full text

Gastrointestinal Oncology, Medicine, Post-hoc Exploratory Analysis +8